In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated travelers diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual, e.g., a human or an animal. The invention also provides devices for delivering a fecal material to a patient.

The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating epilepsy, epileptic seizures and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.

The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating epilepsy, epileptic seizures and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.

The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating primary sclerosing cholangitis and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.

The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating primary sclerosing cholangitis and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.

In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated travelers diarrhea, or C.difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual, e.g., a human or an animal. The invention also provides devices for delivering a fecal material to a patient.

In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated travelers diarrhea, or C.difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual, e.g., a human or an animal. The invention also provides devices for delivering a fecal material to a patient.

Provided are a whole bacteria capsule, a preparation method therefor and a use thereof. The preparation method comprises the steps of: (1) screening fecal bacteria donors using high-throughput sequencing; (2) collecting feces of the fecal bacteria donors screened in step (1), and preparing a fecal bacterial liquid; and (3) mixing the fecal bacterial liquid prepared in step (2) with a freeze-drying protective agent, cooling, freezing and vacuum-drying the mixture, and loading the freeze-dried feces bacteria powder obtained into a capsule shell to obtain the whole bacteria capsule. By screening the fecal bacteria donors using high-throughput sequencing, fecal bacteria donors can be quickly screened for different fecal bacteria receptors, and the whole bacteria capsule prepared can accurately match with the fecal bacteria receptors.

Provided are a whole bacteria capsule, a preparation method therefor and a use thereof. The preparation method comprises the steps of: (1) screening fecal bacteria donors using high-throughput sequencing; (2) collecting feces of the fecal bacteria donors screened in step (1), and preparing a fecal bacterial liquid; and (3) mixing the fecal bacterial liquid prepared in step (2) with a freeze-drying protective agent, cooling, freezing and vacuum-drying the mixture, and loading the freeze-dried feces bacteria powder obtained into a capsule shell to obtain the whole bacteria capsule. By screening the fecal bacteria donors using high-throughput sequencing, fecal bacteria donors can be quickly screened for different fecal bacteria receptors, and the whole bacteria capsule prepared can accurately match with the fecal bacteria receptors.

Methods of preventing and treating COVID-19 infection by administering probiotics. The probiotics can be administered via the following methods: fecal transplant, suppository, or orally. The probiotic contains one or more of the following microorganisms: Bifidobacterium, Clostridium, Veillonella, Ruminococcus, and Sutterella.